It is known that PGE synthase, also known as prostaglandin E synthase, is made up of a group of at least three structurally and biologically distinct enzymes. PGE synthase converts prostaglandin H2 (PGH2), which is produced by cyclooxygenase (COX), to PGE2. PGES that are associated with membranes include mPGES-1, mPGES-2, and cytosolic PGES (cPGES).
Perinuclear mPGES-1 is a protein that, like COX-2, is markedly upregulated by proinflammatory stimuli and downregulated by anti-inflammatory glucocorticoids. It has a clear functional preference for COX-2 over COX-1. The Golgi membrane-associated protein mPGES-2 is synthesized, and the N-terminal hydrophobic domain is removed by proteolysis to create a mature cytosolic enzyme. This enzyme is functionally coupled with both COX-1 and COX-2 and is expressed rather constitutively in a variety of cells and tissues. cPGES is functionally linked to COX-1 to encourage immediate PGE2 production, and it is constitutively expressed in a wide range of cell types.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V84672 | (+)-ε-Viniferin | 129170-22-5 | |
|
V88751 | 1-O-Hexadecylglycerol | 6145-69-3 | 1-O-Hexadecylglycerol can upregulate the expression of PPAR-γ, inhibit pGE2, and exhibit anti-inflammatory properties. |
|
V86981 | 4-Acetylaminoantipyrine | 83-15-8 | 4-Acetylaminoantipyrine (4-AA) is an antipyrine derivative. |
|
V86977 | 5-LO/mPGES1-IN-1 | 1492060-44-2 | 5-LO/mPGES1-IN-1 (Compound 16) is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LO) with IC50 values of 0.3 and 0.4 μM. |
|
V86974 | 5-trans U-44069 | 330796-57-1 | 5-trans U-44069 is the trans isomer of the thromboxane receptor agonist U-44069. |
|
V86976 | 5-trans U-46619 | 330796-58-2 | 5-trans U-46619 is a PGE synthase inhibitor. |
|
V86980 | AF3485 | 1195786-61-8 | AF3485 is a human mPGES-1 inhibitor that exhibits antitumor activity in vitro and in vivo. |
|
V86978 | Anti-inflammatory agent 78 | Anti-inflammatory agent 78 (compound L-37) is a potent anti-inflammatory agent. | |
|
V86979 | Benzydamine | 642-72-8 | Benzydamine is a prostaglandin synthase inhibitor and anti-inflammatory. |
|
V74281 | BRP-201 | 2227434-74-2 | BRP-201 is considered a promising research target for next-generation anti-inflammatory drugs to study inflammatory diseases and is a new, potent and specific inhibitor of mPGES-1 with IC50 of 0.42 μM. |
|
V74282 | Clopirac | 42779-82-8 | Clopirac is a potent and orally bioactive prostaglandin synthetase inhibitor. |
|
V84030 | F092 | 2250261-59-5 | |
|
V74278 | Friluglanstat | 1422203-86-8 | Friluglanstat is a prostaglandin E synthase (mPGES-1) inhibitor (antagonist) with anti~inflammatory activity. |
|
V2882 | HPGDS inhibitor 1 | 1033836-12-2 | HPGDS Inhibitor I (also known as H-PGDS inhibitor 1) is a novel, orally bioavailable, potent and selective inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS) with IC50 Value of 0.7 nM. |
|
V31708 | HPGDS inhibitor 2 | 2101626-26-8 | HPGDS inhibitor 2 (GSK2894631A) is a novel, potent, highly potent and selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with an IC50 of 9.9 nM. |
|
V4638 | limaprost | 74397-12-9 | Limaprost (formerly ONO1206; OP1206; ONO-1206; OP-1206) is, an alprostadil (prostaglandin E1) analogue, is a novel and potent vasodilator that increases blood flow and inhibits platelet aggregation. |
|
V74284 | Limaprost-d3 (Limaprost d3) | 1263190-37-9 | Limaprost-d3 is the deuterium labelled form of Limaprost. |
|
V20408 | MF-63 | 892549-43-8 | MF-63 is a novel and selective mPGES-1 inhibitor. |
|
V74283 | mPGES-1-IN-1 | 2914158-00-0 | MPGES-1 is considered a promising research target for next-generation anti-inflammatory drugs to study inflammatory diseases, and the IC50 of mPGES-1-IN-1 is 0.03 μM. |
|
V86975 | mPGES-1/5-LOX-IN-1 | mPGES-1/5-LOX-IN-1 (compound 3j) is a potent and orally active dual inhibitor of mPGES-1 and 5-LOX with IC50 values of 0.92 and 1.89 µM, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
